Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Simon

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2023
Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]Jonas Ecker, Florian Selt, Dominik Sturm, et al.
Cancers|March 11, 2023
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR ImagesDiana Veiga-Canuto, Leonor Cerdà-Alberich, Ana Jiménez-Pastor, et al.
JCO Precision Oncology|May 26, 2021
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease PanelEsther M van Wezel, Lieke M J van Zogchel, Jalenka van Wijk, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Pediatric Blood & Cancer|July 29, 2024
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter studyAndres F Espinoza, Rochelle Bagatell, Kieran McHugh, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2023
Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]Jonas Ecker, Florian Selt, Dominik Sturm, et al.
Cancers|March 11, 2023
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR ImagesDiana Veiga-Canuto, Leonor Cerdà-Alberich, Ana Jiménez-Pastor, et al.
JCO Precision Oncology|May 26, 2021
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease PanelEsther M van Wezel, Lieke M J van Zogchel, Jalenka van Wijk, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Pediatric Blood & Cancer|July 29, 2024
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter studyAndres F Espinoza, Rochelle Bagatell, Kieran McHugh, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Pageof 13